StreetInsider.com News Articles

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

Thu, 03 Sep 2026 16:05:00 -0400

-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) --

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced that management will participate in two investor conferences taking place in September 2026: the 12th Annual

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

Thu, 03 Sep 2026 16:05:00 -0400

Form 8-K Pasithea Therapeutics For: Aug 20

Fri, 21 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260821/26962355.html

Form 8-K Pasithea Therapeutics For: Aug 20

Fri, 21 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260821/26962355.html

Form 10-Q Pasithea Therapeutics For: Jun 30

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931586.html

Form 10-Q Pasithea Therapeutics For: Jun 30

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931586.html

Form SCHEDULE 13G/A Pasithea Therapeutics Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26930108.html

Form SCHEDULE 13G/A Pasithea Therapeutics Filed by: Vivo Opportunity Fund Holdings, L.P.

Fri, 14 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26930108.html

Form DEF 14A Pasithea Therapeutics For: Sep 09

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892198.html

Form DEF 14A Pasithea Therapeutics For: Sep 09

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892198.html

Form ARS Pasithea Therapeutics For: Dec 31

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892207.html

Form ARS Pasithea Therapeutics For: Dec 31

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892207.html

Form SCHEDULE 13G/A Pasithea Therapeutics Filed by: Opaleye Management Inc.

Fri, 31 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260731/26850635.html

Form SCHEDULE 13G/A Pasithea Therapeutics Filed by: Opaleye Management Inc.

Fri, 31 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260731/26850635.html

Form PRE 14A Pasithea Therapeutics For: Jul 29

Wed, 29 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260729/26836489.html

Form PRE 14A Pasithea Therapeutics For: Jul 29

Wed, 29 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260729/26836489.html

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

Tue, 21 Jul 2026 07:00:00 -0400

-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026

-- Full abstract will be published on ESMO website per Congress’ standard embargo schedule

MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1),

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

Tue, 21 Jul 2026 07:00:00 -0400

-- Full abstract will be published on ESMO website per Congress’ standard embargo schedule

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit